Zacks Research Issues Positive Estimate for Glaukos Earnings

Glaukos Corporation (NYSE:GKOS – Free Report) – Research analysts at Zacks Research boosted their Q1 2028 earnings per share estimates for shares of Glaukos in a report released on Wednesday, November 18th. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings of $0.27 per share for the quarter, up from their previous forecast of $0.18. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Glaukos’ current full-year earnings is $0.64 per share. Zacks Research also issued estimates for Glaukos’ Q2 2028 earnings at $0.45 EPS.

Glaukos (NYSE:GKOS – Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.57. Glaukos had a negative return on equity of 0.97% and a negative net margin of 24.60%. The business had revenue of $211.03 million during the quarter, compared to analyst estimates of $168.04 million. During the same period in the prior year, the business earned ($0.16) earnings per share. The business’s revenue was up 58.0% compared to the same quarter last year.

A number of other research analysts have also recently commented on GKOS. Wells Fargo & Company upped their price objective on Glaukos from $178.00 to $226.00 and gave the company an “overweight” rating in a report on Thursday, October 29th. Wall Street Zen raised Glaukos from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 7th. Piper Sandler restated an “overweight” rating and issued a $240.00 target price (up from $195.00) on shares of Glaukos in a research report on Thursday, October 29th. Mizuho set a $225.00 target price on Glaukos in a research report on Thursday, October 29th. Finally, Needham & Company LLC upped their price target on Glaukos from $201.00 to $251.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $218.00.

Get Our Latest Stock Analysis on Glaukos

Glaukos Stock Performance

Shares of Glaukos stock opened at $237.24 on Thursday. The business’s 50 day moving average price is $190.92 and its 200 day moving average price is $150.09. The company has a current ratio of 4.57, a quick ratio of 4.09 and a debt-to-equity ratio of 0.09. Glaukos has a one year low of $93.78 and a one year high of $255.18.

Institutional Trading of Glaukos

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Voya Investment Management LLC boosted its holdings in Glaukos by 0.3% in the third quarter. Voya Investment Management LLC now owns 16,976 shares of the medical instruments supplier’s stock valued at $2,787,000 after purchasing an additional 49 shares during the period. Allworth Financial LP increased its holdings in Glaukos by 27.3% during the 3rd quarter. Allworth Financial LP now owns 252 shares of the medical instruments supplier’s stock worth $41,000 after purchasing an additional 54 shares during the period. Parallel Advisors LLC increased its holdings in Glaukos by 14.4% during the 3rd quarter. Parallel Advisors LLC now owns 438 shares of the medical instruments supplier’s stock worth $72,000 after purchasing an additional 55 shares during the period. State of Wyoming increased its holdings in Glaukos by 6.8% during the 3rd quarter. State of Wyoming now owns 1,030 shares of the medical instruments supplier’s stock worth $169,000 after purchasing an additional 66 shares during the period. Finally, Fulcrum Asset Management LLP raised its position in Glaukos by 91.7% in the 3rd quarter. Fulcrum Asset Management LLP now owns 184 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 88 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Insider Activity at Glaukos

In other news, CEO Thomas Burns sold 180,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 18th. The shares were sold at an average price of $236.89, for a total value of $42,640,200.00. Following the sale, the chief executive officer directly owned 65,060 shares of the company’s stock, valued at approximately $15,412,063.40. The trade was a 73.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Joseph E. Gilliam sold 861 shares of the business’s stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $250.00, for a total transaction of $215,250.00. Following the completion of the sale, the chief operating officer directly owned 71,602 shares in the company, valued at $17,900,500. This trade represents a 1.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 243,278 shares of company stock valued at $58,105,705 in the last ninety days. Insiders own 5.90% of the company’s stock.

Glaukos News Roundup

Investors following GKOS have been watching these news items:

  • Positive Sentiment: Zacks Research lifted its FY2026 EPS estimate to $0.42 from a forecasted loss of $0.43, and its FY2027 estimate to $1.24 from $0.45. It also raised its FY2028 forecast to $2.24 from $1.70 and increased estimates for multiple quarters. The revisions suggest improved expectations for earnings growth, although they come from one research firm. Glaukos analyst estimates
  • Negative Sentiment: COO Joseph Gilliam sold 861 shares for about $215,000 at $250 per share, reducing his stake by 1.19%. The sale may weigh modestly on sentiment, but he still owned 71,602 shares after the transaction. Insider sale report

Glaukos Company Profile

(Get Free Report)

Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.

Featured Articles

Earnings History and Estimates for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.